SynAct Pharma AB (SYNACT) - Cash Flow Conversion Efficiency

Latest as of March 2026: -0.170x

Based on the latest financial reports, SynAct Pharma AB (SYNACT) has a cash flow conversion efficiency ratio of -0.170x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-32.95 Million ≈ $-3.55 Million USD) by net assets (Skr193.75 Million ≈ $20.85 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See SYNACT equity financing ratio to measure how much of total assets are equity-financed.

SynAct Pharma AB - Cash Flow Conversion Efficiency Trend (2016–2025)

This chart illustrates how SynAct Pharma AB's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check SYNACT cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.

SynAct Pharma AB Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of SynAct Pharma AB ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Titan Minerals Ltd AU:TTM	-0.013x
Idsud S.A PA:ALIDS	-0.907x
Indústrias Romi S.A SA:ROMI3	-0.005x
Coda Octopus Group Inc NASDAQ:CODA	0.009x
Nordhealth AS OL:NORDH	-0.008x
Crosswood PA:CROS	-0.020x
Alterity Therapeutics Ltd AU:ATH	-0.196x
Riber S.A PA:ALRIB	-0.100x

Annual Cash Flow Conversion Efficiency for SynAct Pharma AB (2016–2025)

The table below shows the annual cash flow conversion efficiency of SynAct Pharma AB from 2016 to 2025. For the full company profile with market capitalisation and key ratios, see SYNACT company net worth.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	Skr170.29 Million ≈ $18.33 Million	Skr-97.33 Million ≈ $-10.47 Million	-0.572x	-37.23%
2024-12-31	Skr214.17 Million ≈ $23.05 Million	Skr-89.20 Million ≈ $-9.60 Million	-0.416x	+26.75%
2023-12-31	Skr176.19 Million ≈ $18.96 Million	Skr-100.18 Million ≈ $-10.78 Million	-0.569x	+38.81%
2022-12-31	Skr126.52 Million ≈ $13.62 Million	Skr-117.56 Million ≈ $-12.65 Million	-0.929x	+70.17%
2021-12-31	Skr20.87 Million ≈ $2.25 Million	Skr-65.00 Million ≈ $-6.99 Million	-3.115x	-48.68%
2020-12-31	Skr15.87 Million ≈ $1.71 Million	Skr-33.24 Million ≈ $-3.58 Million	-2.095x	-75.44%
2019-12-31	Skr13.50 Million ≈ $1.45 Million	Skr-16.12 Million ≈ $-1.74 Million	-1.194x	+49.15%
2018-12-31	Skr10.31 Million ≈ $1.11 Million	Skr-24.21 Million ≈ $-2.61 Million	-2.348x	-76.25%
2017-12-31	Skr12.91 Million ≈ $1.39 Million	Skr-17.20 Million ≈ $-1.85 Million	-1.332x	-144.84%
2016-12-31	Skr27.08 Million ≈ $2.91 Million	Skr-14.73 Million ≈ $-1.59 Million	-0.544x	--

About SynAct Pharma AB

ST:SYNACT Sweden Biotechnology

Market Cap

$108.83 Million

Skr1.01 Billion SEK

Market Cap Rank

#18826 Global

#327 in Sweden

Share Price

Skr18.06

Change (1 day)

-1.10%

52-Week Range

Skr10.66 - Skr24.95

All Time High

Skr143.40